Next Article in Journal
Cross-Sectional Study on the Sero- and Viral Dynamics of Porcine Circovirus Type 2 in the Field
Next Article in Special Issue
A Canine-Directed Chimeric Multi-Epitope Vaccine Induced Protective Immune Responses in BALB/c Mice Infected with Leishmania infantum
Previous Article in Journal
Features of the Human Antibody Response against the Respiratory Syncytial Virus Surface Glycoprotein G
Previous Article in Special Issue
Technological Approaches for Improving Vaccination Compliance and Coverage
Open AccessArticle

Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa

1
Viral Vectors and Vaccines Bioprocessing Group, Department of Bioengineering, McGill University, Montreal, QC H3A 0G4, Canada
2
Research and Development Department, National Veterinary Institute, P.O. Box 19 Debre Zeit, Ethiopia
3
Group of Biotechnology Development, Institut Pasteur de Tunis, 13, Place Pasteur, B.P. 74, 1002 Tunis, Tunisia
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(2), 338; https://doi.org/10.3390/vaccines8020338
Received: 29 May 2020 / Revised: 20 June 2020 / Accepted: 22 June 2020 / Published: 26 June 2020
Developing vaccine technology platforms to respond to pandemic threats or zoonotic diseases is a worldwide high priority. The risk of infectious diseases transmitted from wildlife and domestic animals to humans makes veterinary vaccination and animal health monitoring highly relevant for the deployment of public health global policies in the context of “one world, one health” principles. Sub-Saharan Africa is frequently impacted by outbreaks of poultry diseases such as avian influenza and Newcastle Disease (ND). Here, an adenovirus-vectored vaccine technology platform is proposed for rapid adaptation to ND or other avian viral threats in the region. Ethiopian isolates of the Newcastle Disease virus (NDV) were subjected to sequence and phylogenetic analyses, enabling the construction of antigenically matched vaccine candidates expressing the fusion (F) and hemagglutinin-neuraminidase (HN) proteins. A cost-effective vaccine production process was developed using HEK293 cells in suspension and serum-free medium. Productive infection in bioreactors (1–3 L) at 2 × 106 cells/mL resulted in consistent infectious adenoviral vector titers of approximately 5–6 × 108 TCID50/mL (approximately 1011VP/mL) in the harvest lysates. Groups of chickens were twice immunized with 1 × 1010 TCID50 of the vectors, and full protection against a lethal NDV challenge was provided by the vector expressing the F antigen. These results consolidate the basis for a streamlined and scalable-vectored vaccine manufacturing process for deployment in low- and medium-income countries. View Full-Text
Keywords: Newcastle Disease virus; adenovirus vaccine; vaccine manufacturing; bioreactor production; HEK293; veterinary vaccination; vaccine production platform Newcastle Disease virus; adenovirus vaccine; vaccine manufacturing; bioreactor production; HEK293; veterinary vaccination; vaccine production platform
Show Figures

Figure 1

MDPI and ACS Style

Farnós, O.; Gelaye, E.; Trabelsi, K.; Bernier, A.; Subramani, K.; Kallel, H.; Yami, M.; Kamen, A.A. Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa. Vaccines 2020, 8, 338.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop